Tapering bDMARDs in axial SpA - what is the current evidence?
- PMID: 30903025
- DOI: 10.1038/s41584-019-0201-2
Tapering bDMARDs in axial SpA - what is the current evidence?
Comment on
-
Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.Arthritis Res Ther. 2019 Jan 8;21(1):11. doi: 10.1186/s13075-018-1772-z. Arthritis Res Ther. 2019. PMID: 30621746 Free PMC article. Clinical Trial.
References
-
- Sieper, J. & Poddubnyy, D. Axial spondyloarthritis. Lancet 390, 73–84 (2017). - DOI
-
- Smolen, J. S. et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann. Rheum. Dis. 73, 6–16 (2014). - DOI
-
- Gratacós, J. et al. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. Arthritis Res. Ther. 21, 11 (2019). - DOI
-
- Van Der Heijde, D. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 76, 978–991 (2017). - DOI
-
- Rudwaleit, M. et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777–783 (2009). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources